Navigation Links
Osteoporosis drug may help treat advanced hormone-sensitive breast cancer
Date:6/17/2013

A new osteoporosis drug hinders the growth of estrogen-sensitive cancer that has become resistant to treatment with tamoxifen, a study in mice shows. The results will be presented Saturday at The Endocrine Society's 95th Annual Meeting in San Francisco.

The medication, bazedoxifene, which is approved in Europe under the brand name Conbriza for the treatment and prevention of postmenopausal osteoporosis, also reduced estrogen activity and estrogen receptor levels in cultured human breast cancer cells, the study authors reported.

"Bazedoxifene, a known, safe drug approved in Europe, may present a near-term option as an effective therapy for breast cancer in patients who have relapsed during treatment with tamoxifen or aromatase inhibitors," said Suzanne Wardell, PhD, the study's principal investigator and a research scientist at Duke University, Durham, N.C.

About 70 percent of breast cancers are hormone sensitive, the National Cancer Institute estimates, meaning they need female hormones like estrogen to grow. In one-third to one-half of these patients, the cancer becomes resistant to medications that block either estrogen production or activity of the estrogen receptor, according to Wardell, who said, "These women then have few treatment options."

Treatment options include systemic, or whole-body, chemotherapy or often-painful injections of an anti-estrogen drug, fulvestrant into the buttocks muscle.

The investigators reasoned that one or more drugs known as selective estrogen receptor modulators, or SERMs, might prove effective in treating breast tumors that have developed resistance to hormone blockers. Most SERMs have anti-estrogen effects on some tissues and estrogen-like effects on other tissues. The new SERM bazedoxifene stimulates the estrogen receptor in bone to retain bone mineral density but inhibits estrogen receptor activation in the breast and uterus, Wardell said.

Wardell's team tested bazedoxifene in a study funded by the drug's manufacturer, Pfizer. First, they applied standard molecular biology techniques to multiple models of human-derived breast cancer cell lines. The models included cancer cells that were resistant to tamoxifen, aromatase inhibitors and lapatinib, a drug used to treat aggressive HER2-positive breast cancer. In all models, bazedoxifene reportedly inhibited estrogen-induced gene expression and cell proliferation.

The researchers then transplanted the cultured breast tumors into immune-compromised mice. Wardell said that bazedoxifene "completely inhibited the estrogen receptor-dependent tumor growth," not only in tumors that had never received tamoxifen treatment but also in those that were resistant to tamoxifen. The drug deterred tumor growth to a similar extent as reported for fulvestrant, she said.

The ideal next research step, according to Wardell, would be a clinical trial to evaluate the efficacy of bazedoxifene in patients with metastatic, hormone therapy-resistant breast cancer.

Pfizer has applied for U.S. Food and Drug Administration approval of bazedoxifene but only when combined with conjugated estrogens for treatment of postmenopausal symptoms and prevention of postmenopausal osteoporosis, she said.


'/>"/>

Contact: Aaron Lohr
alohr@endocrine.org
240-482-1380
The Endocrine Society
Source:Eurekalert

Related medicine news :

1. Simple Ways to Protect Yourself from the Risks of Osteoporosis
2. Nearly 30 percent of women fail to pick up new prescriptions for osteoporosis, study finds
3. Osteoporosis costs EU countries €37 billion every year
4. New scorecard shows inequalities in osteoporosis care in the Europe Union
5. Registration opens for Asia-Pacifics largest medical conference on osteoporosis
6. Smoking and depressive symptoms in adolescent girls are red flag for postmenopausal osteoporosis
7. Are there racial disparities in osteoporosis screening and treatment?
8. Teen smoking decreases bone accumulation in girls, may increase osteoporosis risk
9. Men with belly fat at risk for osteoporosis
10. Men May Benefit From Osteoporosis Drug, Too: Study
11. Has osteoporosis treatment failed when a fracture occurs?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the ... Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , “We ... new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/25/2016)... ... , ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter ... bar too high can result in disappointment, perhaps even self-loathing. However, those who set ... , Research from PsychTests.com reveals that behind the tendency to set low ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced ... feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as a ... has released tools for healthy coping following a traumatic event. , Trauma sufferers tend ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her son ... lash out at his family verbally and physically. , “When something upset him, he couldn’t ... would use it. He would throw rocks at my other children and say he was ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 ... appointment of Dr. Edward Futcher to ... Director, effective June 23, 2016.Dr. Futcher was also ... and Governance Committees.  As a non-executive member of ... expertise and strategic counsel to VolitionRx in connection ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... report to their offering. ... failure, it replaces the function of kidneys by removing the ... the treatment helps to keep the patient body,s electrolytes such ... Increasing number of ESRD patients & substantial healthcare expenditure on ...
(Date:6/23/2016)... -- In a startling report released today, National Safety Council ... comprehensive, proven plan to eliminate prescription opioid overdoses. Prescription ... are tackling the worst drug crisis in recorded U.S. history, assigned ... Kentucky , New Mexico , ... 28 failing states, three – Michigan , ...
Breaking Medicine Technology: